research use only
Cat.No.S4237
|
In vitro |
DMSO
: 91 mg/mL
(199.85 mM)
Water : 91 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 455.34 | Formula | C15H21N3O.2H3O4P |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 63-45-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2.OP(=O)(O)O.OP(=O)(O)O | ||
| In vitro |
Primaquine is still the only transmission-blocking anti-malarial clinically available, displaying a marked activity against gametocytes of all species of human malaria, including multi-resistant Plasmodium falciparum strains. Primaquine is also effective against all exoerythrocytic forms of the parasite and is used in conjunction with other anti-malarials for the treatment of vivax and ovale malaria. The exact mechanism by which Primaquine so effectively eliminates Plasmodium falciparum and gametocytes is still unknown, but it is thought that metabolism at the parasites’ mitochondria is impaired, eventually by interference with the ubiquinone function as an electron carrier in the respiratory chain. Another potential mechanism of anti-malarial action by Primaquine is the production of highly reactive metabolites that generate intracellular oxidative potentials. Primaquine is found to be an inhibitor of vesicular transport and blocks the calcium-release-activated current in rat megakaryocytes. Primaquine also acts on cardiac Na+ channels in isolated rat ventricular muscle and myocytes. Primaquine inhibits protein transport with IC50 of 50 μM, and inhibits the budding of vesicles from the donor membranes. PQ has a strong inhibitory effect on the recycling of endocytosed proteins to the plasma membrane. Primaquine is able to inhibit the potassium current by blockade of muscarinic receptors. Primaquine also inhibit human erythrocyte membrane acetylcholinesterase (AChE) with IC33 of 30 μM.
Primaquine is a nitrite-reacting mutagen precursor where the secondary amino group plays a key role.
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05879224 | Recruiting | Vivax Malaria|G6PD Deficiency |
Menzies School of Health Research|Gadjah Mada University|Universitas Sumatera Utara|Indonesia University|Yayasan Pengembangan Kesehatan dan Masyarakat|Indonesian National Malaria Control Program Ministry of Health|National Research and Innovation Agency of Indonesia|Burnet Institute|University of Melbourne|Medicines for Malaria Venture|PATH|UNITAID|Institute of Tropical Medicine Belgium |
August 7 2023 | Not Applicable |
| NCT04984759 | Withdrawn | Healthy Lactating Women |
University of Oxford|Mahidol Oxford Tropical Medicine Research Unit |
July 1 2023 | Phase 4 |
| NCT05874271 | Recruiting | Vivax Malaria|G6PD Deficiency |
Macfarlane Burnet Institute for Medical Research and Public Health Ltd|Papua New Guinea Institute of Medical Research|Papua New Guinea National Department of Health|Menzies School of Health Research|University of Melbourne|Medicines for Malaria Venture|PATH|UNITAID |
July 10 2023 | Not Applicable |
| NCT05044637 | Recruiting | Malaria Vivax |
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado|Bill and Melinda Gates Foundation|Conselho Nacional de Desenvolvimento Científico e Tecnológico |
August 26 2021 | Phase 2 |
| NCT04073953 | Unknown status | G6PD Deficiency |
University of Mississippi Oxford|University of Colorado Denver|Southern Research Institute |
September 1 2020 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.